Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain DVAX message board posts where the ticker symbol DVAX has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest DVAX SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-036802 Size: 4 KB
2018-06-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-036800 Size: 4 KB
2018-06-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-036799 Size: 4 KB
2018-06-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-036798 Size: 4 KB
2018-06-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-036796 Size: 4 KB
2018-06-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-036794 Size: 6 KB
2018-06-08
S-8  Documents Securities to be offered to employees in employee benefit plans
Acc-no: 0001193125-18-188034 (33 Act)  Size: 118 KB
2018-06-08 333-225525
18889452
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001193125-18-183849 (34 Act)  Size: 24 MB
2018-06-05 001-34207
18880016
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-035377 Size: 6 KB
2018-06-04
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-035376 Size: 6 KB
2018-06-04
More DVAX SEC Filings


Related news from
Mon, 11 Jun 2018
10:30:00 +0000
Dynavax to Present at the William Blair 38th Annual Growth Stock Conference
BERKELEY, Calif., June 11, 2018-- Dynavax Technologies Corporation today announced that Michael Ostrach, Dynavax’ s Chief Financial Officer, will present at the William Blair 38th Annual Growth Stock Conference ...
Sun, 10 Jun 2018
18:00:00 +0000
Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector
The huge American Society of Clinical Oncology or ASCO confab has called it a wrap for another year. Keytruda to treat PD-1-naive advanced melanoma patients. Dynavax's main asset for the time being is Heplisav-B, a hepatitis B vaccine approved by the FDA late in 2017.
Mon, 04 Jun 2018
21:06:20 +0000
What Did Dynavax Technologies Corporation’s (NASDAQ:DVAX) CEO Take Home Last Year?
Eddie Gray took the helm as Dynavax Technologies Corporation’s (NASDAQ:DVAX) CEO and grew market cap to US$993.27M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
Mon, 04 Jun 2018
18:15:00 +0000
Dynavax Reports Data for Phase 1b/2 Trial of SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Overall Response Rate of 70% and 6- month Progression Free Survival rate of 76% in Patients Naïve to Anti-PD-1 Treatment who Received the≤ 2 mg Dose of SD -101. Combination showed Similar Rates of Immune-related ...
Sat, 19 May 2018
18:00:00 +0000
4 Names to Watch Ahead of This Year's Key Cancer-Research Conference
The American Society of Clinical Oncology conference -- the biggest event of the year for oncology firms and investors -- kicks off June 1 in Chicago, and scores of firms typically release abstracts right around now of studies that they'll be presenting at the event, which is known as "ASCO." that means a myriad of oncology names have either already moved or will soon do so on these reports. It presented promising data last year around its compound larotrectinib -- news that eventually parlayed its way into a $1.5 billion collaboration deal with Bayer. This year, Loxo will report that an early stage Phase 1 trial involved a compound called LOXO-292 showed a 69% overall response rate among RET-positive patients with non-small-cell lung cancer and a type of thyroid cancer.
Thu, 17 May 2018
16:51:11 +0000
Should Dynavax Technologies Corporation’s (NASDAQ:DVAX) Recent Earnings Worry You?
Assessing Dynavax Technologies Corporation’s (NASDAQ:DVAX) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple sense check toRead More...
Wed, 16 May 2018
21:15:00 +0000
Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting
Abstract Data Show Overall Response Rate of 60% in 25 Advanced Melanoma Patients Naïve to Anti-PD-1 Therapy. Poster Presentation to Include Data from a Total of over 50 Patients and Will Compare SD-101 ...
Wed, 16 May 2018
12:30:00 +0000
Market Trends Toward New Normal in Dynavax Technologies, Synergy Resources, Allscripts Healthcare Solutions, Plug Power, GameStop, and Newfield Exploration — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, May 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dynavax ...
Mon, 14 May 2018
21:51:50 +0000
Edited Transcript of DVAX earnings conference call or presentation 8-May-18 8:30pm GMT
Q1 2018 Dynavax Technologies Corp Earnings Call
Thu, 10 May 2018
16:18:26 +0000
JPMorgan Sees Entry Point In Dynavax Ahead Of June Oncology Conference
The American Society of Clinical Oncology's 2018 annual meeting is scheduled to be held in Chicago, Illinois June 1-5. In a Thursday note, JPMorgan evaluated the prospects for Dynavax Technologies Corporation ...
Wed, 09 May 2018
09:03:31 +0000
Dynavax Technologies: 1Q Earnings Snapshot
On a per-share basis, the Berkeley, California-based company said it had a loss of 63 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Tue, 08 May 2018
20:05:00 +0000
Dynavax Reports First Quarter 2018 Financial Results
Update on Initial Progress of HEPLISAV-B ® Commercial Launch. Conference Call to be Held at 4:30pm ET/1: 30 pm PT. BERKELEY, Calif., May 08, 2018-- Dynavax Technologies Corporation today reported financial ...
Mon, 07 May 2018
13:07:32 +0000
Dynavax Technologies Corporation (NASDAQ:DVAX) Is Expected To Breakeven
Dynavax Technologies Corporation’s (NASDAQ:DVAX): Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The US$1.02BRead More...
Mon, 07 May 2018
10:30:00 +0000
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Dynavax Technologies Corporation (DVAX) today announced that on May 1, 2018 the Compensation Committee of Dynavax’s Board of Directors (the “Committee”) approved the grant of inducement stock options to purchase an aggregate of 79,000 shares of common stock to 10 new employees, and on May 3, 2018, the Committee approved the grant of inducement stock options to purchase an additional 10,000 shares of common stock to two new employees.  These awards were granted pursuant to the Dynavax Technologies Corporation Inducement Plan, as an inducement material to the new employees entering into employment with Dynavax, in accordance with the NASDAQ Listing Rule 5635(c)(4).
Wed, 02 May 2018
20:15:00 +0000
Dynavax to Host First Quarter 2018 Financial Results Conference Call
Dynavax Technologies Corporation (DVAX) today announced that it will report financial results for the first quarter ended March 31, 2018 after market close on Tuesday, May 8, 2018, and host a conference call that day to review the results and provide a business update at 4:30pm ET/1:30pm PT. To access the call, participants must dial (866) 548-4713 in the U.S. or (323) 794-2093 internationally, and use the conference ID 8635193. The conference ID for the replay will be 8635193.
Wed, 25 Apr 2018
11:50:00 +0000
Wired News – CDC Publishes Dynavax’s HEPLISAV-B(R) ACIP Recommendations in Morbidity and Mortality Weekly Report
LONDON, UK / ACCESSWIRE / April 25, 2018 / Active-Investors.com has just released a free research report on Dynavax Technologies Corp. (NASDAQ: DVAX) ("Dynavax"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=DVAX as the Company's latest news hit the wire. On April 23, 2018, the Company announced that the Centers for Disease Control and Prevention (CDC) has published the Advisory Committee of Immunization Practices' (ACIP) Recommendations for the use of HEPLISAV-B® [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for adults in the US, in the Morbidity and Mortality Weekly Report (MMWR) dated April 19, 2018.
Mon, 23 Apr 2018
10:30:00 +0000
Dynavax’s HEPLISAV-B® ACIP Recommendations Published in the CDC’s Morbidity and Mortality Weekly Report
BERKELEY, Calif., April 23, 2018-- Dynavax Technologies Corporation today announced that the Centers for Disease Control and Prevention published the Advisory Committee of Immunization Practices’ Recommendations ...
Tue, 17 Apr 2018
13:07:39 +0000
Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting
Demonstrates potential to achieve long-term, systemic responses Combination therapy was well tolerated Additional SD-101 data in head and neck squamous cell carcinoma presented at AACR. BERKELEY, Calif., ...
Mon, 16 Apr 2018
21:28:17 +0000
11 Stocks Moving In Monday's After-Hours Session
Gainers: NF Energy Saving Corp (NASDAQ: NFEC ) shares are up 8 percent after a 13-D filing from Bi Yongquan showed a 19.8-percent stake.  Dynavax Technologies Corporation (NASDAQ: DVAX ) shares are up ...
Mon, 16 Apr 2018
18:10:15 +0000
Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck
BERKELEY, Calif., April 16, 2018-- Dynavax Technologies Corporation today announced data from its ongoing Phase 1 b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This is a site for sharing information about the atypical investments that the majority of investors have not discovered. It is about finding the next value/growth sector/investment before all the major houses on the Street are recommending it." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards